Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions

University Hospital, Ghent61 enrolled

Overview

The goal of this trial is to evaluate the effect of the prone crawl treatment position and/or accelerated schedule on acute and late toxicities, as well as quality of life and time management for breast cancer patients receiving whole breast and regional nodal irradiation after breast conserving surgery.

Locoregional radiotherapy after lumpectomy and axillary node dissection diminishes the locoregional recurrence risk at 10 years by 21,2 % in women with pathologically confirmed lymph node involvement. Excess dose to organs at risk can lead to acute and late side effects, such as tissue damage, organ malfunction and secondary cancers. Radiotherapy in prone position has helped reduce these risks for whole breast radiotherapy only, but has not yet been adequately investigated for patients also requiring regional nodal irradiation. One of the reasons is that there is no optimal patient support device available to allow regional nodal irradiation in prone position. To this end, a novel positioning device was developed at our center, allowing regional nodal irradiation in prone position. It was called the crawl breast couch because the patient position resembles a phase from the crawl swimming technique. A previous planning study by Deseyne et al. using this device shows a benefit (i.e. reduced dose) for the ipsilateral lung, the thyroid, as well as a minor benefit for the right lung, and contralateral breast (which already receive very low relative doses) while maintaining similar target coverage when compared to supine positioning. Apart from the paradigm shift from supine to prone radiotherapy, in recent years, it has become clear that breast cancer cells are more sensitive to fraction dose than originally presumed. Large randomized trials confirm this hypothesis: moderate hypofractionation schemes in 15 or 16 fractions are at least equivalent in tumor control and toxicity although the total dose is lower than the traditional 50 Gy in 25 fractions. Further acceleration to 5 fractions is expected to have an even larger radiobiological advantage regarding tumor control. Additional advantages are patient comfort and a better use of radiotherapy resources. This randomized trial with 2 x 2 factorial design tests 2 interventions for patients with breast cancer requiring whole-breast and regional nodal irradiation: radiotherapy in prone position with a specifically designed patient support device called the crawl breast couch, and accelerated radiotherapy in 5 fractions. The standard arm in this trial is supine hypofractionated radiotherapy. The goal of this trial is to evaluate the effect of the prone crawl treatment position and/or accelerated schedule on acute and late toxicities, as well as quality of life and time management for breast cancer patients receiving whole breast and regional nodal irradiation after breast conserving surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Neoplasms Radiotherapy Lymph Node Metastases

Interventions

Prone RadiotherapyDEVICE

Prone positioning for regional nodal irradiation using the crawl breast couch.

AccelerationRADIATION

Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost

Supine RadiotherapyDEVICE

Supine positioning for regional nodal irradiation using breastboard.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Breast conserving surgery * AND Multidisciplinary decision of adjuvant whole breast + regional nodal irradiation * AND Informed consent obtained, signed and dated before specific protocol procedures Exclusion Criteria: * Mastectomy * OR Bilateral breast irradiation * OR Distant metastasis/metastases * OR previous irradiation to the thoracic, cervical or axillary region and overlap of fields with current treatment * OR life expectancy of less than 2 years * OR pre-existing conditions or comorbidities making toxicity evaluation difficult, e.g. skin disorders * OR pregnant or breast feeding * OR mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study * OR patient unlikely to complete the study

Locations (1)

Radiotherapy department, UZ Ghent

Ghent, Oost-Vlaanderen, Belgium

Outcomes

Primary Outcomes

Breast retraction

Rate of breast retraction or volume loss after radiotherapy

Time frame: 2 years after radiotherapy